Published in N Engl J Med on September 22, 2011
Nonsteroidal anti-inflammatory drug use, chronic liver disease, and hepatocellular carcinoma. J Natl Cancer Inst (2012) 3.69
Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver. J Clin Invest (2012) 3.14
Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria. Liver Transpl (2014) 3.11
Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell (2013) 3.08
Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol (2014) 2.74
Identification of liver transplant candidates with hepatocellular carcinoma and a very low dropout risk: implications for the current organ allocation policy. Liver Transpl (2013) 2.53
Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology (2014) 2.40
Epidemiology of hepatocellular carcinoma in the United States: where are we? Where do we go? Hepatology (2014) 2.34
ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development. Cancer Cell (2014) 2.31
Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas. Gut (2014) 2.19
Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet (2015) 2.17
Factors associated with outcomes and response to therapy in patients with infiltrative hepatocellular carcinoma. Clin Gastroenterol Hepatol (2013) 2.11
MicroRNAs regulate methionine adenosyltransferase 1A expression in hepatocellular carcinoma. J Clin Invest (2012) 1.86
A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration. Gut (2014) 1.84
Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma. Hepatology (2014) 1.76
Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. Oncologist (2012) 1.76
Cell death and cell death responses in liver disease: mechanisms and clinical relevance. Gastroenterology (2014) 1.73
Charged particle therapy--optimization, challenges and future directions. Nat Rev Clin Oncol (2013) 1.70
Mutations in SPRTN cause early onset hepatocellular carcinoma, genomic instability and progeroid features. Nat Genet (2014) 1.68
The association between metabolic syndrome and hepatocellular carcinoma: systemic review and meta-analysis. J Clin Gastroenterol (2014) 1.57
Medical therapies for hepatocellular carcinoma: a critical view of the evidence. Nat Rev Gastroenterol Hepatol (2012) 1.57
Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. Nat Immunol (2015) 1.54
Hepatic Arterial Infusion of Low-Density Lipoprotein Docosahexaenoic Acid Nanoparticles Selectively Disrupts Redox Balance in Hepatoma Cells and Reduces Growth of Orthotopic Liver Tumors in Rats. Gastroenterology (2015) 1.53
Understanding the costs of cancer care before and after diagnosis for the 21 most common cancers in Ontario: a population-based descriptive study. CMAJ Open (2013) 1.51
Intention to treat outcome of T1 hepatocellular carcinoma with the "wait and not ablate" approach until meeting T2 criteria for liver transplant listing. Liver Transpl (2016) 1.49
p62/SQSTM1 by Binding to Vitamin D Receptor Inhibits Hepatic Stellate Cell Activity, Fibrosis, and Liver Cancer. Cancer Cell (2016) 1.47
Treatment of hepatocellular carcinoma: a systematic review. Liver Cancer (2012) 1.47
Paracrine signals from liver sinusoidal endothelium regulate hepatitis C virus replication. Hepatology (2013) 1.47
Underestimation of liver-related mortality in the United States. Gastroenterology (2013) 1.46
Hepatocellular Carcinoma From Epidemiology to Prevention: Translating Knowledge into Practice. Clin Gastroenterol Hepatol (2015) 1.45
Comparison of clinical manifestations and outcomes between hepatitis B virus- and hepatitis C virus-related hepatocellular carcinoma: analysis of a nationwide cohort. PLoS One (2014) 1.45
Trends in relative survival in patients with a diagnosis of hepatocellular carcinoma in Ontario: a population-based retrospective cohort study. CMAJ Open (2015) 1.43
A nonrandomized cohort and a randomized study of local control of large hepatocarcinoma by targeting intratumoral lactic acidosis. Elife (2016) 1.43
Inter-regulation of IGFBP1 and FOXO3a unveils novel mechanism in ursolic acid-inhibited growth of hepatocellular carcinoma cells. J Exp Clin Cancer Res (2016) 1.41
Heregulin-1ß and HER3 in hepatocellular carcinoma: status and regulation by insulin. J Exp Clin Cancer Res (2016) 1.38
Yttrium-90 Radioembolization for Hepatocellular Carcinoma Prior to Liver Transplantation. World J Surg (2017) 1.36
Chemopreventive strategies in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol (2013) 1.36
Tumor-associated macrophages produce interleukin 6 and signal via STAT3 to promote expansion of human hepatocellular carcinoma stem cells. Gastroenterology (2014) 1.35
The diagnosis and treatment of hepatocellular carcinoma. Dtsch Arztebl Int (2014) 1.29
AEG-1/MTDH/LYRIC: clinical significance. Adv Cancer Res (2013) 1.27
Prognosis of patients with hepatocellular carcinoma. Validation and ranking of established staging-systems in a large western HCC-cohort. PLoS One (2012) 1.25
2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma. Gut Liver (2015) 1.23
Circulation long non-coding RNAs act as biomarkers for predicting tumorigenesis and metastasis in hepatocellular carcinoma. Oncotarget (2015) 1.22
Utilization of metabolomics to identify serum biomarkers for hepatocellular carcinoma in patients with liver cirrhosis. Anal Chim Acta (2012) 1.20
Emerging trends in hepatocellular carcinoma: focus on diagnosis and therapeutics. Clin Med Insights Oncol (2014) 1.17
Epigenetic regulation of MicroRNA-122 by peroxisome proliferator activated receptor-gamma and hepatitis b virus X protein in hepatocellular carcinoma cells. Hepatology (2013) 1.14
2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma. Korean J Radiol (2015) 1.14
Lack of association of two common polymorphisms rs2910164 and rs11614913 with susceptibility to hepatocellular carcinoma: a meta-analysis. PLoS One (2012) 1.12
The Indian National Association for Study of the Liver (INASL) Consensus on Prevention, Diagnosis and Management of Hepatocellular Carcinoma in India: The Puri Recommendations. J Clin Exp Hepatol (2014) 1.12
Surveillance, diagnosis, treatment, and outcome of liver cancer in Japan. Liver Cancer (2015) 1.12
Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. Oncotarget (2014) 1.11
LC-MS/MS-based serum proteomics for identification of candidate biomarkers for hepatocellular carcinoma. Proteomics (2015) 1.11
Hepatocellular carcinoma: natural history, current management, and emerging tools. Biologics (2012) 1.10
Liver and diabetes. A vicious circle. Hepatol Res (2013) 1.10
Comparison of artificial neural network and logistic regression models for predicting in-hospital mortality after primary liver cancer surgery. PLoS One (2012) 1.10
YAP Inhibition Restores Hepatocyte Differentiation in Advanced HCC, Leading to Tumor Regression. Cell Rep (2015) 1.08
Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: implications for the treatment of human liver cancer. Cell Cycle (2013) 1.08
LC-MS profiling of N-Glycans derived from human serum samples for biomarker discovery in hepatocellular carcinoma. J Proteome Res (2014) 1.08
High Expression of FLOT1 Is Associated with Progression and Poor Prognosis in Hepatocellular Carcinoma. PLoS One (2013) 1.08
MicroRNA-302b suppresses cell proliferation by targeting EGFR in human hepatocellular carcinoma SMMC-7721 cells. BMC Cancer (2013) 1.07
The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance. PLoS One (2013) 1.06
Prognostic factors for hepatocellular carcinoma recurrence. World J Gastroenterol (2014) 1.06
From cirrhosis to hepatocellular carcinoma: new molecular insights on inflammation and cellular senescence. Liver Cancer (2013) 1.05
MicroRNA-31 functions as a tumor suppressor by regulating cell cycle and epithelial-mesenchymal transition regulatory proteins in liver cancer. Oncotarget (2015) 1.05
Long non-coding RNA URHC regulates cell proliferation and apoptosis via ZAK through the ERK/MAPK signaling pathway in hepatocellular carcinoma. Int J Biol Sci (2014) 1.05
Total laparoscopic limited anatomical resection for centrally located hepatocellular carcinoma in cirrhotic liver. Surg Endosc (2012) 1.05
Natural history of untreatable hepatocellular carcinoma: A retrospective cohort study. World J Hepatol (2012) 1.04
Phase I/II study of immunotherapy using tumor antigen-pulsed dendritic cells in patients with hepatocellular carcinoma. Int J Oncol (2012) 1.04
Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma. Semin Cancer Biol (2014) 1.04
Inflammation- and stress-related signaling pathways in hepatocarcinogenesis. World J Gastroenterol (2012) 1.04
NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma. Cell Mol Immunol (2014) 1.04
The EGFR signalling system in the liver: from hepatoprotection to hepatocarcinogenesis. J Gastroenterol (2013) 1.04
Treatment for hepatocellular carcinoma in Japan over the last three decades: Our experience and published work review. Hepatol Res (2014) 1.03
Insufficient radiofrequency ablation promotes epithelial-mesenchymal transition of hepatocellular carcinoma cells through Akt and ERK signaling pathways. J Transl Med (2013) 1.02
Neutrophil-lymphocyte ratio predicts the prognosis of patients with hepatocellular carcinoma after liver transplantation. World J Gastroenterol (2013) 1.02
NEMO Prevents Steatohepatitis and Hepatocellular Carcinoma by Inhibiting RIPK1 Kinase Activity-Mediated Hepatocyte Apoptosis. Cancer Cell (2015) 1.02
AEG-1/MTDH/LYRIC in liver cancer. Adv Cancer Res (2013) 1.01
Transarterial chemoembolization and bland embolization for hepatocellular carcinoma. World J Gastroenterol (2014) 1.01
Genome-wide screening identified that miR-134 acts as a metastasis suppressor by targeting integrin β1 in hepatocellular carcinoma. PLoS One (2014) 1.01
Epigenetics in hepatocellular carcinoma: an update and future therapy perspectives. World J Gastroenterol (2014) 1.00
CT and MR imaging diagnosis and staging of hepatocellular carcinoma: part I. Development, growth, and spread: key pathologic and imaging aspects. Radiology (2014) 1.00
Interferon-stimulated gene 15 (ISG15) is a trigger for tumorigenesis and metastasis of hepatocellular carcinoma. Oncotarget (2014) 1.00
Laparoscopic approach for hepatocellular carcinoma: where is the limit? Chin J Cancer Res (2014) 1.00
Validation of a coding algorithm to identify patients with hepatocellular carcinoma in an administrative database. Pharmacoepidemiol Drug Saf (2012) 1.00
The DNA damage checkpoint protein ATM promotes hepatocellular apoptosis and fibrosis in a mouse model of non-alcoholic fatty liver disease. Cell Cycle (2012) 1.00
Focus on: ethnicity and the social and health harms from drinking. Alcohol Res (2013) 0.99
Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma. Oncologist (2016) 0.99
HBx-related long non-coding RNA DBH-AS1 promotes cell proliferation and survival by activating MAPK signaling in hepatocellular carcinoma. Oncotarget (2015) 0.99
Small heterodimer partner overexpression partially protects against liver tumor development in farnesoid X receptor knockout mice. Toxicol Appl Pharmacol (2013) 0.99
Hepatocellular carcinoma: A comprehensive review. World J Hepatol (2015) 0.98
Japan's Successful Model of Nationwide Hepatocellular Carcinoma Surveillance Highlighting the Urgent Need for Global Surveillance. Liver Cancer (2012) 0.98
Clinical utility of plasma glypican-3 and osteopontin as biomarkers of hepatocellular carcinoma. Gut Liver (2013) 0.98
Hepatic stellate cell coculture enables sorafenib resistance in Huh7 cells through HGF/c-Met/Akt and Jak2/Stat3 pathways. Biomed Res Int (2014) 0.97
Genetic and epigenetic aspects of initiation and progression of hepatocellular carcinoma. World J Gastroenterol (2015) 0.97
Comparing staging systems for predicting prognosis and survival in patients with hepatocellular carcinoma in Egypt. PLoS One (2014) 0.97
Treatment for hepatocellular carcinoma in elderly patients: a literature review. J Cancer (2013) 0.97
High fat diet feeding results in gender specific steatohepatitis and inflammasome activation. World J Gastroenterol (2014) 0.96
Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma. J Hepatol (2014) 0.96
Maraviroc, a CCR5 antagonist, prevents development of hepatocellular carcinoma in a mouse model. PLoS One (2013) 0.96